EFTA01092527Set 9
2012-07-163p899w
trio of new venture
investors: Hatteras Venture Partners of Durham, N.C.; MedImmune
Ventures of Gaithersburg, MD (the corporate venture arm of AstraZeneca
Ltd); and Ascent Biomedical Ventures of New York ... poorly met,
diseases."
Commenting for the new investors, Michael Gutch, Ph.D., Managing Director
of MedImmune Ventures, stated, "After extensive technical diligence we
were all convinced of the enormous potential
https://www.justice.gov/epstein/files/DataSet%209/EFTA01092527.pdf